Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus‐1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub‐study A5334s-Reference-Cited by-同舟云学术

Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus‐1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub‐study A5334s

Published:2019-12-12 Issue:1 Volume:86 Page:132-142
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Venuto Charles S.¹^ORCID,Cramer Yoninah S.²,Rosenkranz Susan L.²,Sulkowski Mark³,Wyles David L.⁴,Cohen Daniel E.⁵,Schmidt Jeffrey⁵,Alston‐Smith Beverly L.⁶,Morse Gene D.⁷

Affiliation:

1. University of Rochester Rochester NY USA

2. Harvard TH Chan School of Public Health Boston MA USA

3. Johns Hopkins University Baltimore MD USA

4. Denver Health Medical Center Denver CO USA

5. AbbVie, Inc North Chicago IL USA

6. National Institutes of Health Bethesda MD USA

7. University at Buffalo Buffalo NY USA

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Wiley